Jump to content

FDA News: ASA404 Has Entered Phase III Trial for NSCLC


Recommended Posts

http://fdanews.com/newsletter/article?i ... eId=106015

Daily Bulletin News:

. . . . . . . . .

Novartis Starts Trial for ASA404 in Lung Cancer

Novartis’ nonsmall cell lung cancer drug ASA404 has entered a Phase III trial.

The multinational, randomized, double-blind, placebo-controlled study will evaluate ASA404 in combination with paclitaxel and carboplatin as a first-line treatment for locally advanced or metastatic nonsmall cell lung cancer.

ASA404 is one of six oncology compounds the company is developing. The other therapies include RAD001 (renal cell carcinoma and other cancers), SOM230 (Cushing’s disease/refractory carcinoid tumors, acromegaly), LBH589 (cutaneous T-cell lymphoma and other cancers), EPO906 (ovarian cancer) and PKC412 (acute myelogenous leukemia and aggressive systemic mastocytosis), according to the company.

. . . . . . . . .

(FDA News, Daily Bulletin, April 21, 2008)


The information contained in these articles may or may not be in agreement with my own opinions. They are not posted as medical advice of any kind.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.